All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 204 of 206 pages ‹ First < 202 203 204 205 206 >
HSL19658
 Angell M
 A epidemia de doença mental
 Edição 59 2011
 
http://revistapiaui.estadao.com.br/edicao-59/questoes-medico-farmacologicas/a-epidemia-de-doenca-mental
HSL19666
 Ariely D
 Dan Ariely: Beware conflicts of interest
 TED.com 2011 Aug
 
http://www.ted.com/talks/dan_ariely_beware_conflicts_of_interest.html?awesm=on.ted.com_9daV#.TmSznHlzNTQ.facebook
HSL19680
 Henrique Prezzi S
  Drotrecogina na Sepse - Contraponto
 Medicina Hospitalar 2007
 
http://www.medicinahospitalar.com.br/Aulas/ContrapontoDotrecogina/Drotrecogina_files/intro.htm
HSL19684
 Moynihan R.
 Payments to doctors in Australia are to be scrutinised after marketing tactics are exposed.
 BMJ 2011 18;343:d6714:
  doi: 10.1136/bmj.d6714. No abstract available.
http://www.bmj.com/content/343/bmj.d6714.long
HSL19685
 Moynihan R.
 Is journalism the drug industry's new dance partner?
 BMJ 2011 2;343:d6978:
  doi: 10.1136/bmj.d6978. No abstract available.
http://www.bmj.com/content/343/bmj.d6978.long
HSL19700
 Australian Government
 TGA reforms: A blueprint for TGA’s future
 2011 Dec
 
http://www.tga.gov.au/pdf/media-2011-tga-reforms-111208.pdf
HSL19701
 Schofferman J.
 The medical-industrial complex, professional medical associations, and continuing medical education.
 Pain Med 2011;12:(12):1713-9
  doi: 10.1111/j.1526-4637.2011.01282.x. Epub 2011 Dec 6.
http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2011.01282.x/abstract;jsessionid=2442C14B5DA9F2C8FEA0ACD80B235B3B.d02t02
HSL19710
 Ben Goldacre: Combatendo ciência ruim
 TED.com 2011 Sep0
 
http://www.ted.com/talks/lang/pt-br/ben_goldacre_battling_bad_science.html
HSL19721
 Moskop JC, Iserson KV, Aswegan AL, Larkin GL, Schears RM.
 Gifts to Physicians From Industry: The Debate Evolves.
 Ann Emerg Med 2011 27;
 
http://www.sciencedirect.com/science/article/pii/S0196064411014120
HSL19722
 Jutel A, Menkes DB.
 'But doctors do it...': nurses' views of gifts and information from the pharmaceutical industry
 Ann Pharmacother. 2009;43:(6):1057-63
 
http://www.theannals.com/content/43/6/1057.long
HSL19723
 Rodwin MA.
 Reforming pharmaceutical industry-physician financial relationships: lessons from the United States, France, and Japan.
 J Law Med Ethics 2011;39:(4):662-70
  doi: 10.1111/j.1748-720X.2011.00633.x.
http://onlinelibrary.wiley.com/doi/10.1111/j.1748-720X.2011.00633.x/abstract;jsessionid=87F44D2C068F3A098926CD3CA202E752.d04t03
HSL19739
 Manchanda P, Wittink Dr, Ching A, Cleanthous P, Ding M, Dong XJ, Leeflang PSH, Misra S, Mizik N, Narayanan S, Steenburgh T, Wieringa JE, Wosinska M, Xie Y,
 Understanding Firm, Physician and Consumer Choice Behaviour in the Health Care Industry
 Sixth Invitational Choice Symposium hosted by the University of Colorado 2004 Sep
 
www.springerlink.com/index/518wvx08320847g5.pdf
HSL19743
 Pieters T.
 About media, audiences and marketing medicines: the interferons.
 Clio Med 2002;66:229-43:
 
http://www.ncbi.nlm.nih.gov/pubmed/12028679
HSL19744
 Jones J
 Medical Publishing: Part 3
 PMLive.com 2002
 
HSL19745
 Ed.
 Drug promotion: stealth, wealth, and safety.
 Lancet 1993 12;341:(8859):1507-8
 
http://www.sciencedirect.com/science/article/pii/014067369390637V
HSL19750
 Rosenberg CE.
 The tyranny of diagnosis: specific entities and individual experience.
 Milbank Q 2002;80:(2):237-60
 
http://onlinelibrary.wiley.com/doi/10.1111/1468-0009.t01-1-00003/abstract;jsessionid=5B9815EFE8B821B590EAA5D146EE29DB.d01t02?systemMessage=Wiley+Online+Library+will+be+disrupted+14+Jan+from+10-12+GMT+for+monthly+maintenance
HSL19751
 Greenhalgh T.
 Beware cloth devils.
 BMJ 2000 8;
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1127742/?tool=pubmed
HSL19752
 Flower R.
 Lifestyle drugs: pharmacology and the social agenda.
 Trends Pharmacol Sci 2004;25:(4):182-5
 
http://www.sciencedirect.com/science/article/pii/S0165614704000549
HSL19755
 Lexchin J.
 Lifestyle drugs: issues for debate.
 CMAJ 2001 15;164:(10):1449-51
 
http://www.cmaj.ca/content/164/10/1449.long
HSL19756
 Starcevic V.
 Opportunistic 'Rediscovery' of mental disorders by the pharmaceutical industry.
 Psychother Psychosom 2002;71:(6):305-10
 
http://content.karger.com/produktedb/produkte.asp?DOI=65989&typ=pdf
HSL19759
 Villanueva P, Peiró S, Librero J, Pereiró I.
 Accuracy of pharmaceutical advertisements in medical journals.
 Lancet 2003 4;361:(9351):27-32
 
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2912118-6/fulltext
HSL19779
 Wolfsthal SD, Beasley BW, Kopelman R, Stickley W, Gabryel T, Kahn MJ; Membership Survey and Scientific Data Committee, The Association of Program Directors of Internal Medicine.
 Benchmarks of support in internal medicine residency training programs.
 Acad Med 2002;77:(1):50-6
 
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=PWVKtY1YDSjYJptRs49jD2dLTnsMb4S3HdnYYvvfJLdw2hQRJG1H!-1165837873!181195629!8091!-1?issn=1040-2446&volume=77&issue=1&spage=50
HSL19795
 Huston P, Moher D.
 Redundancy, disaggregation, and the integrity of medical research.
 Lancet 1996 13;347:(9007):1024-6
 
http://www.ncbi.nlm.nih.gov/pubmed/8606568
HSL19798
 Wilmshurst P.
 Publication bias.
 Lancet 1991 8;337:(8754):1419
 
http://www.sciencedirect.com/science/article/pii/014067369193110U
HSL19811
 Durand M
 Reality Check: Is It Newsworthy?
 Pharma Exec 2003 Apr
 
pharmexec.findpharma.com/
HSL19832
 AMSA move on code
 Australian Medicine 2004  May 174
 
HSL19833
 Abraham J.
 Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK.
 Soc Sci Med 2002;55:(9):1671-90
 
http://linkinghub.elsevier.com/retrieve/pii/S0277953602001600
HSL19835
 Brotzman GL, Mark DH.
 The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities.
 J Gen Intern Med 1993;8:(3):130-4
 
http://www.ncbi.nlm.nih.gov/pubmed/8455108
HSL19847
 Taylor B.
 Giveaway drugs: good intentions, bad design.
 Health Aff (Millwood) 2004;23:(1):213-7
 
http://content.healthaffairs.org/content/23/1/213.long
HSL19850
 Finaly L
 Just Like a Woman
 Fashion Date uncertain 200477-78
 
HSL19853
 Chapman S
 Not biting the hand that feeds you. Tobacco advertising and editorial bias in Australian newspapers.
 MJA 1984 14;480
 
http://www.ncbi.nlm.nih.gov/pubmed/6708868
HSL19854
 Pharmaceutical sponsorship of practice newsletters called into question
 Medical Forum 2002 Dec10
 
HSL19855
 McNeil JJ, Grabsch EA, McDonald MM
 Postmarketing surveillance: strengths and limitations.The flucloxacillin-dicloxacillin story.
 Med J Aust. 1999 Mar 15;170:(60):270-3
 
http://www.ncbi.nlm.nih.gov/pubmed/10212650
HSL19861
 Stauber J, Rampton S
 The Public Relations Industry's Secret War on Activists
 Covert Action Quarterly 1995
 
http://mediafilter.org/caq/Caq55.prwar.html
HSL19862
 Caudill TS, Johnson MS, Rich EC, McKinney WP.
 Physicians, pharmaceutical sales representatives, and the cost of prescribing.
 Arch Fam Med 1996;5:(4):201-6
 
http://www.ncbi.nlm.nih.gov/pubmed/8769907
HSL19863
 Wenley S
 Free drug offer puts pressure on GPs to prescribe
 GP Date uncertain Before 2000 4
 
HSL19872
 Meyers D.
 Doctors, research funds and marketing.
 Med J Aust 1995 3;162:(7):392
 
http://www.ncbi.nlm.nih.gov/pubmed/7715534
HSL19873
 Mansfield P
 Pushing expensive new drugs
 Consuming Interest 2001 00 00;
 
HSL19874
 Mansfield P
 Pushing expensive new drugs
 Consuming Interest 20010
 
HSL19875
 Cassels A
 Donuts for doctors: Buying the medical profession
 Common Ground 2005 Sep
 
http://www.commonground.ca/iss/0509170/cg170_donuts.shtml
HSL19876
 Cialdini RB
 The Science of Persuasion 
 Scientific American 2001 Feb
 
http://www.scientificamerican.com/article.cfm?id=the-science-of-persuasion
HSL19888
 Skolnick AA.
 WHO considers regulating ads, sale of medical products on Internet.
 JAMA 1997 3;278:(21):1723-4
 
http://www.ncbi.nlm.nih.gov/pubmed/9388131
HSL19889
 Josefson D.
 Bayer made to tone down aspirin advertisements.
 West J Med 2000;172:(3):154
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1070790/?tool=pubmed
HSL19890
 Jaillon P.
 The control of prescription drug advertising: a controversial issue.
 Clin Pharmacol Ther 2000;68:(6):583-5
 
http://www.nature.com/clpt/journal/v68/n6/full/clpt2000137a.html
HSL19898
 endurance.
 In the heartburn wars: speed vs endurance.
 Consum Rep 2004;69:(3):49
 
http://www.ncbi.nlm.nih.gov/pubmed/15005092
HSL19899
 McGavock H, Webb CH, Johnston GD, Milligan E.
 Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.
 BMJ 1993 30;307:(6912):1118-20
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1679086/?tool=pubmed
HSL19900
 Hogerzeil HV, Couper MR, Gray R.
 Guidelines for drug donations.
 BMJ 1997 8;314:(7082):737-40
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2126144/?tool=pubmed
HSL19903
 Schouten E
 Drug donations must be strictly regulated. Georgia has tight guidelines.
 BMJ 1995 9;311:(7006):684
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551444/?tool=pubmed
HSL19908
 Berckmans P, Dawans V, Schmets G, Vandenbergh D, Autier P.
 Inappropriate drug-donation practices in Bosnia and Herzegovina, 1992 to 1996.
 N Engl J Med 1997 18;337:(25):1842-5
 
http://www.nejm.org/doi/full/10.1056/NEJM199712183372512
HSL19909
 Weir D
 Let the Buyer Beware! The New Therapeutic Goods Advertising Code Heralds. Changes in Advertising Medicines.
 Health Issues 63 2000 Jun
 
HSL19920
 Metzl J
 'Mother's Little Helper': The Crisis of Psychoanalysis and the Miltown Resolution
 Gender & History 2003 Aug15:(2):228–255
 
http://onlinelibrary.wiley.com/doi/10.1111/1468-0424.00300/abstract
HSL19942
 Weeks WB, Wallace AE, Kimberly BC
 The changing face of pharmaceutical advertising: A look at medical journals reveals a new era in advertising.
 Marketing Health Services 2001;27-30
 
http://www.ncbi.nlm.nih.gov/pubmed/11525138
HSL19943
 Davis I.
 Inadvertent placement of advertisements.
 Med J Aust 1994 6;160:(11):727
 
http://www.ncbi.nlm.nih.gov/pubmed/8202012
HSL19945
 Muldoon C.
 Pharmaceutical advertising: fact or fiction?
 Pharmacoepidemiol Drug Saf 2004;13:(11):801-2
 
http://onlinelibrary.wiley.com/doi/10.1002/pds.1011/abstract
HSL19947
 Fassold RW, Gowdey CW.
 A survey of physicians' reactions to drug promotion.
 Can Med Assoc J 1968 6;98:(14):701-5
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924002/?tool=pubmed
HSL19951
 Marwick C.
 Federal funding for comparative drug studies not in US budget.
 BMJ 2004 13;328:(7440):603
 
http://www.bmj.com/content/328/7440/603.1?view=long&pmid=15016678
HSL19970
 Naeem S
 Direct promotion to patients?
 The Network of Association for Rational Use of Medication in Pakistan 1997 10
 
HSL19971
 Bangash SM
 Wrong claims and medical patronage
 The Network of Association for Rational Use of Medication in Pakistan 1997
 
HSL19973
 Designing A Prescription Drug Benefit
 Health Affairs 2004;23:(1):123
 
http://content.healthaffairs.org/content/23/1/123.full
HSL19975
 Iglehart JK
 An Industry Under Siege Mounts Counterattack
 Health Affairs 2004 00 00;23:(1):7
 
http://content.healthaffairs.org/content/23/1/7.full
HSL19982
 Hindle D.
 Are Australia's drugs too cheap for our own good?
 Aust Health Rev 2001;24:(2):4-6
 
http://www.publish.csiro.au/index.cfm?paper=AH010004
HSL19983
 Dalton A.
 Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
 Aust Health Rev 2001;24:(2):7-14
 
www.publish.csiro.au/index.cfm?paper=AH010007
HSL19985
 Viney R.
 Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
 Aust Health Rev 2001;24:(2):21-4
 
http://www.publish.csiro.au/index.cfm?paper=AH010021
HSL19986
 Hartigan-Go K.
 The pharmaceutical situation in the Philippines.
 Aust Health Rev 2001;24:(2):25-31
 
http://www.publish.csiro.au/index.cfm?paper=AH010025
HSL19988
 Gilsdorf JR.
 As drug marketing pays off, my mother pays up.
 Health Aff (Millwood) 2004;23:(1):208-12
 
http://content.healthaffairs.org/content/23/1/208.long
HSL19991
 Lenzer J.
 Stockholders protest Pfizer's drug prices.
 CMAJ 2004 6;171:(1):24
 
http://www.cmaj.ca/content/171/1/24.2.long
HSL19994
 McNamara S
 Antidepressant research divides experts
 MJA Insight 2012 03 12;(9):
 
http://www.mjainsight.com.au/view?post=antidepressant-research-divides-experts&post_id=8416&cat=issue-9-12-march-2012
HSL20002
 Drug Advertising Wars
 Action Network (A Publication of the Australian Pensioners' & Superannuants' Federation 1996 Mar
 
HSL20004
 Lexchin J.
 The siren call of new drugs.
 Expert Rev Pharmacoecon Outcomes Res 2003;3:(5):513-5
 
http://www.expert-reviews.com/doi/abs/10.1586/14737167.3.5.513
HSL20006
 Dodd P, Dexter T
 Reasons for not seeing drug representatives. Companies have to encourage doctors to prescribe their products.
 BMJ 1993 9;319:(7215):69-70
 
http://www.ncbi.nlm.nih.gov/pubmed/10576840
HSL20013
 Tiner R
 Reasons for not seeing drug representatives: They should be seen because they are a good resource.
 BMJ 1999 9;319:(7215):1002
 
http://www.bmj.com/content/319/7215/1002?view=long&pmid=10514174
HSL20015
 Newton-Syms FA, Dawson PH, Cooke J, Feely M, Booth TG, Jerwood D, Calvert RT.
 The influence of an academic representative on prescribing by general practitioners.
 Br J Clin Pharmacol 1992;33:(1):69-73
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1381201/?tool=pubmed
HSL20025
 Lexchin J.
 Interactions between doctors and pharmaceutical sales representatives.
 Can J Clin Pharmacol 2001;8:(2):64-5
 
http://www.ncbi.nlm.nih.gov/pubmed/11493932
HSL20031
 Preston NW.
 Publication bias via suppressed expert conflict.
 Lancet 1993 17;341:(8851):1031
 
http://www.ncbi.nlm.nih.gov/pubmed/8096921
HSL20032
 Haynes S
 Pharma relationship healthy
 Medical Observer 2005 Jan15
 
HSL20040
 Jorm AF.
 Gifts from the pharmaceutical industry.
 Med J Aust 1997 7;166:(7):386-7
 
http://www.ncbi.nlm.nih.gov/pubmed/9137287
HSL20041
 Goodman B.
 All rationalizations large and small.
 Am J Bioeth 2003;3:(3):57-8
 
http://www.tandfonline.com/doi/abs/10.1162/15265160360706624?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
HSL20067
 Halperin JA.
 Medicine, pharmacy, and industry--a fly's eye view of health care.
 Ann Pharmacother 1995;29:(9):925-33
 
http://www.ncbi.nlm.nih.gov/pubmed/8547743
HSL20068
 Huxhagen K
 Pharmacy and Drug Companies - An alliance with some problems
 Information to Pharmacists 2003 Sep
 
http://www.computachem.com.au/i2P/emag/Issue19/Article7.shtml
HSL20087
 Siegel L
 DTC Advertising: Bane...or Blessing?
 Pharmaceutical Executive  2000 Oct140-152
 
http://business.highbeam.com/137364/article-1G1-66355685/dtc-advertising-bane-blessing
HSL20117
 Peters J
 Hard to swallow: The high cost of direct-to-consumer advertising.
 Minnesota Medicine 2001;84:
 
http://www.ncbi.nlm.nih.gov/pubmed/11202520
HSL20121
 DTC ads hotly debated
 Pharmacy Today 2001 Jan3, 12
 
HSL20124
 Tudiver S
 Advertising Prescription Drugs to Consumers: Why women should be wary of direct advertising of drugs
 A Friend Indeed 2001 Mar1-3
 
http://www.straightgoods.ca/ViewConsForum.cfm?REF=259&Cookies=yes
HSL20125
 Advertising Prescription Drugs
 Which Online 2001
 
HSL20128
 Panckhurst P
 Inside the drug wars
 AdMedia 2000 July
 
http://www.archivesearch.co.nz/?webid=adm&articleid=2983
HSL20148
 Hollon MF.
 Direct-to-consumer advertising: a haphazard approach to health promotion.
 JAMA 2005 27;293:(16):2030-3
 
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.293.16.2030
HSL20151
 McNee W.
 More on DTCA and the cost of asthma inhalers.
 N Z Med J 2003 7;116:(1185):U673
 
http://www.ncbi.nlm.nih.gov/pubmed/14615811
HSL20152
 Griffiths IJ.
 Opponents of DTCA need the objectivity they expect of advertisers.
 N Z Med J 2003 10;116:(1183):U641
 
http://www.ncbi.nlm.nih.gov/pubmed/14581950
HSL20157
 Medsafe to report on advert self regulation
 Pharmacology Today 2000 Apr8
 
HSL20158
 New legislation
 Pharmacy Today 2000 Apr1-2
 
HSL20160
 Medwar C
 Because you're worth it
 Health Matters Date uncertain 20007
 
HSL20162
 Tsao JC.
 Informational and symbolic content of over-the-counter drug advertising on television.
 J Drug Educ 1997;27:(2):173-97
 
http://www.ncbi.nlm.nih.gov/pubmed/9270212
HSL20166
 Law J
 Preparing to advertise directly to the European consumer
 Scrip 1999 Nov6
 
HSL20179
 Collier J.
 Conflicts between pharmaceutical company largesse and patients' rights.
 Med Leg J 1992;60:
 
http://www.ncbi.nlm.nih.gov/pubmed/1480006
HSL20188
 Gönül FF, Carter F, Wind J.
 What kind of patients and physicians value direct-to-consumer advertising of prescription drugs.
 Health Care Manag Sci 2000;3:(3):215-26
 
http://www.ncbi.nlm.nih.gov/pubmed/10907324
HSL20206
 Black F.
 Teaching rational prescribing.
 Aust Fam Physician 1996;25:(7):1097-9
 
http://www.ncbi.nlm.nih.gov/pubmed/8768276
HSL20207
 Bhatt AD.
 Drug promotion and doctor: a relationship under change?
 J Postgrad Med 1993;39:(3):120-3
 
http://www.ncbi.nlm.nih.gov/pubmed/8051638
HSL20209
 Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA
 Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group.
 BMJ 1998 15;317:
 
http://www.bmj.com/content/317/7156/465?view=long&pmid=9703533
HSL20210
 Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.
 An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
 J Ment Health Policy Econ 2002;5:(1):3-19
 
http://www.icmpe.net/fulltext.php?volume=5&page=3&year=2002&num=1&name=Berndt%20ER
HSL20211
 Bergus GR, Chapman GB, Levy BT, Ely JW, Oppliger RA.
 Clinical diagnosis and the order of information.
 Med Decis Making 1998;18:(4):412-7
 
http://mdm.sagepub.com/content/18/4/412.long
Page 204 of 206 pages ‹ First < 202 203 204 205 206 >
 








 


